nach oben

Schweizer Gastroenterologie

Erschienen in:

14.05.2020 | Morbus Crohn | Originalien

Therapiealgorithmen für die Behandlung des Morbus Crohn im klinischen Alltag

verfasst von: PD Dr. med. Michael Christian Sulz, Joel Duetschler, Frank Seibold

Erschienen in: Schweizer Gastroenterologie | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Therapie des oft schubförmig verlaufenden und nicht heilbaren Morbus Crohn ist komplex und sollte auf den einzelnen Patienten individuell abgestimmt werden. Gerade komplizierte Verläufe (z. B. mit komplexer perianaler Fistelbildung) sind anspruchsvolle Situationen im klinischen Alltag. Das medikamentöse Therapiearmamentarium wurde in den letzten Jahren durch neue Wirkstoffe erweitert, die nun auch in den internationalen Richtlinien positioniert werden. Trotz der individualisierten Therapie ist es im klinischen Alltag hilfreich, Algorithmen zur besseren Entscheidungsfindung beiziehen zu können. In dieser Arbeit werden 3 Algorithmen zu verschiedenen klinischen Szenarien in der Therapie des Morbus Crohn mit dem Fokus auf die endoluminale Inflammation präsentiert und die neuen Therapieoptionen in diesen Algorithmen positioniert.

Vorheriger Artikel Aktueller Stand des Kolonkarzinomscreenings (Fokus auf Stuhltest)

Nächster Artikel COVID-19 aus der Sicht der Gastroenterologie

Crohn BB, Ginzburg L, Oppenheimer GD (2000) Regional ileitis: a pathologic and clinical entity. 1932. Mt Sinai J Med 67(3):263–268PubMed

Stark R, König HH, Leidl R (2006) Costs of inflammatory bowel disease in Germany. PharmacoEconomics 24(8):797–814PubMed

Satsangi J, Silverberg MS, Vermeire S et al (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55(6):749–753PubMedPubMedCentral

Maaser C, Sturm A, Vavricka SR et al (2019) ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 13(2):144–164PubMed

Burri E, Beglinger C (2014) The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol 8(2):197–210PubMed

Beaugerie L, Sokol H (2012) Clinical, serological and genetic predictors of inflammatory bowel disease course. World J Gastroenterol 18(29):3806–3813PubMedPubMedCentral

Torres J, Bonovas S, Doherty G et al (2020) ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis 14(1):4–22PubMed

Michetti P, Weinman J, Mrowietz U et al (2017) Impact of treatment-related beliefs on medication adherence in immune-mediated inflammatory diseases: results of the global ALIGN study. Adv Ther 34(1):91–108PubMed

Gomollón F, Dignass A, Annese V et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11(1):3–25PubMed

10.

Gionchetti P, Dignass A, Danese S et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis 11(2):135–149PubMed

11.

Adamina M, Bonovas S, Raine T et al (2020) ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohns Colitis 14(2):155–168. https://doi.org/10.1093/ecco-jcc/jjz187 CrossRefPubMed

12.

Sulz MC, Burri E, Michetti P et al (2020) Treatment algorithms for Crohn’s disease. Digestion. https://doi.org/10.1159/000506364 CrossRefPubMed

13.

Colombel JF, D’Haens G, Lee WJ et al (2020) Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. J Crohns Colitis 14(2):254–266PubMed

14.

Bouguen G, Levesque BG, Pola S et al (2014) Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol 12(6):978–985PubMed

15.

Peyrin-Biroulet L, Sandborn W, Sands BE et al (2015) Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110(9):1324–1338PubMed

16.

Darr U, Khan N (2017) Treat to target in inflammatory bowel disease: an updated review of literature. Curr Treat Options Gastroenterol 15(1):116–125PubMed

17.

Bryant RV, Winer S, Travis SP et al (2014) Systematic review: histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis 8(12):1582–1597PubMed

18.

Nielsen OH, Ainsworth MA (2013) Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 369(8):754–762PubMed

19.

Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317):1541–1549PubMed

20.

D’Haens G, Van Deventer S, Van Hogezand R et al (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 116(5):1029–1034PubMed

21.

Ben-Horin S, Kopylov U, Chowers Y (2014) Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 13(1):24–30PubMed

22.

Fine S, Papamichael K, Cheifetz AS (2019) Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y) 15(12):656–665

23.

Adegbola SO, Sahnan K, Warusavitarne J et al (2018) Anti-TNF therapy in Crohn’s disease. Int J Mol Sci 19(8):2244PubMedCentral

24.

Yarur AJ, Rubin DT (2015) Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases. Inflamm Bowel Dis 21(7):1709–1718PubMed

25.

Poggioli G, Laureti S, Campieri M et al (2007) Infliximab in the treatment of Crohn’s disease. Ther Clin Risk Manag 3(2):301–308PubMedPubMedCentral

26.

Rutgeerts P, Van Assche G, Vermeire S (2004) Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126(6):1593–1610PubMed

27.

Rahier JF, Magro F, Abreu C et al (2014) Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 8(6):443–468PubMed

28.

Wong SH, Gao Q, Tsoi KK et al (2016) Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax 71(1):64–72PubMed

29.

Shukla T, Sands BE (2019) Novel non-biologic targets for inflammatory bowel disease. Curr Gastroenterol Rep 21(5):22PubMed

30.

Weisshof R, El Jurdi K, Zmeter N et al (2018) Emerging therapies for inflammatory bowel disease. Adv Ther 35(11):1746–1762PubMedPubMedCentral

31.

Sandborn WJ, Feagan BG, Rutgeerts P et al (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 369(8):711–721PubMed

32.

Christensen B, Colman RJ, Micic D et al (2018) Vedolizumab as induction and maintenance for inflammatory bowel disease: 12-month effectiveness and safety. Inflamm Bowel Dis 24(4):849–860PubMedPubMedCentral

33.

Baumgart DC, Bokemeyer B, Drabik A et al (2016) Vedolizumab Germany consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice—a nationwide consecutive German cohort study. Aliment Pharmacol Ther 43(10):1090–1102PubMed

34.

Danese S, Sandborn WJ, Colombel JF et al (2019) Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn’s disease. Gastroenterology 157(4):1007–1018.e7PubMed

35.

Verstockt B, Mertens E, Dreesen E et al (2019) Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-TNF naïve and anti-TNF exposed IBD patients. J Crohns Colitis. https://doi.org/10.1093/ecco-jcc/jjz151 CrossRefPubMed

36.

Loftus EV, Colombel J‑F, Feagan BG et al (2019) Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study. Gastroenterology 156(6):182

37.

Ng SC, Hilmi IN, Blake A et al (2018) Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting. Inflamm Bowel Dis 24(11):2431–2441PubMedPubMedCentral

38.

Tarabar D, Hirsch A, Rubin DT (2016) Vedolizumab in the treatment of Crohn’s disease. Expert Rev Gastroenterol Hepatol 10(3):283–290PubMed

39.

Sandborn WJ, Gasink C, Gao LL et al (2012) Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 367(16):1519–1528PubMed

40.

MacDonald JK, Nguyen TM, Khanna R et al (2016) Anti-IL-12/23p40 antibodies for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 11:CD7572PubMed

41.

Engel T, Yung DE, Ma C et al (2019) Effectiveness and safety of ustekinumab for Crohn’s disease; systematic review and pooled analysis of real-world evidence. Dig Liver Dis 51(9):1232–1240PubMed

42.

Feagan BG, Sandborn WJ, Gasink C et al (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375(20):1946–1960PubMed

43.

Tillack C, Ehmann LM, Friedrich M et al (2014) Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 63(4):567–577PubMed

44.

Swissmedic (2020) AW - Anweisung Zulassung Biosimilar HMV4. https://www.swissmedic.ch/dam/swissmedic/de/dokumente/zulassung/zl_hmv_iv/zl101_00_012d_wlverwaltungsverordnunganleitungzulassungaehnliche.pdf.download.pdf/ZL101_00_012d_WL%20Zulassung%20Biosimilar.pdf. Zugegriffen: 1. März 2020

45.

Burri E, Juillerat P, Maillard MH et al (2019) Position statement on the use of biosimilars in inflammatory bowel disease. Swiss Med Wkly 149:w20148PubMed

46.

Danese S, Fiorino G, Raine T et al (2017) ECCO position statement on the use of biosimilars for inflammatory bowel disease—an update. J Crohns Colitis 11(1):26–34PubMed

47.

van der Woude CJ, Ardizzone S, Bengtson MB et al (2015) The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 9(2):107–124PubMed

48.

Reddy D, Murphy SJ, Kane SV et al (2008) Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol 103(5):1203–1209PubMed

49.

Restellini S, Biedermann L, Hruz P et al (2020) Update on the management of inflammatory bowel disease during pregnancy and breastfeeding. Digestion. https://doi.org/10.1159/000502886 CrossRefPubMed

50.

Hruz P, Juillerat P, Kullak-Ublick GA et al (2020) Management of the elderly inflammatory bowel disease patient. Digestion. https://doi.org/10.1159/000503099 CrossRefPubMed

51.

Chung ES, Packer M, Lo KH et al (2003) Anti-TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107(25):3133–3140PubMed

52.

Kalman RS, Hartshorn K, Farraye FA (2015) Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD. Inflamm Bowel Dis 21(2):428–435PubMed

53.

Osterman MT, Sandborn WJ, Colombel JF et al (2014) Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology 146(4):941–949PubMed

54.

Long MD, Martin CF, Pipkin CA et al (2012) Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143(2):390–399.e1PubMed

55.

Siegel CA, Marden SM, Persing SM et al (2009) Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 7(8):874–881PubMedPubMedCentral

56.

Beaugerie L (2013) Use of immunosuppressants and biologicals in patients with previous cancer. Dig Dis 31(2):254–259PubMed

57.

Rezaie A, Kuenzig ME, Benchimol EI et al (2015) Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 6:CD296

58.

Kuenzig ME, Rezaie A, Kaplan GG et al (2018) Budesonide for the induction and maintenance of remission in Crohn’s disease: systematic review and meta-analysis for the Cochrane collaboration. J Can Assoc Gastroenterol 1(4):159–173PubMedPubMedCentral

59.

Burisch J, Goldis A, Kievit L et al (2019) Course of indolent Crohn’s disease in a prospektive European population-based inception cohort with five years follow-up—the EPI-IBD cohort. 7(8). https://doi.org/10.1136/gutjnl-2017-315568

60.

Coward S, Kuenzig ME, Hazlewood G et al (2017) Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn’s disease: a Bayesian network meta-analysis: republished. Inflamm Bowel Dis 23(5):E26–E37PubMed

61.

Benchimol EI, Seow CH, Steinhart AH et al (2008) Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2:CD6792

62.

Gionchetti P, Rizzello F, Annese V et al (2017) Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: clinical practice guidelines of the Italian group for the study of inflammatory bowel disease. Dig Liver Dis 49(6):604–617PubMed

63.

Vavricka SR, Schoepfer AM, Scharl M et al (2014) Steroid use in Crohn’s disease. Drugs 74(3):313–324PubMed

64.

Prefontaine E, Macdonald JK, Sutherland LR (2009) Azathioprine or 6‑mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 4:CD545

65.

Lichtenstein GR, Loftus EV, Isaacs KL et al (2018) ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 113(4):481–517PubMed

66.

Rutgeerts PJ (2001) Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharmacol Ther 15(10):1515–1525PubMed

67.

Tsui JJ, Huynh HQ (2018) Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn’s disease? Ann Gastroenterol 31(4):413–424PubMedPubMedCentral

68.

D’Haens GR, Panaccione R, Higgins PD et al (2011) The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 106(2):199–212 (quiz 213)PubMed

69.

Colombel JF, Sandborn WJ, Rutgeerts P et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132(1):52–65PubMed

70.

Colombel JF, Sandborn WJ, Reinisch W et al (2010) Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 362(15):1383–1395PubMed

71.

Bar-Yoseph H, Waterman M, Almog R et al (2017) Prevention of antidrug antibody formation to Infliximab in Crohn’s patients with prior failure of thiopurines. Clin Gastroenterol Hepatol 15(1):69–75PubMed

72.

Schreiber S (2011) Certolizumab pegol for the treatment of Crohn’s disease. Therap Adv Gastroenterol 4(6):375–389PubMedPubMedCentral

73.

Kucharzik T, Wittig BM, Helwig U et al (2017) Use of intestinal ultrasound to monitor Crohn’s disease activity. Clin Gastroenterol Hepatol 15(4):535–542.e2PubMed

74.

Ricciuto A, Dhaliwal J, Walters TD et al (2018) Clinical outcomes with therapeutic drug monitoring in inflammatory bowel disease: a systematic review with meta-analysis. J Crohns Colitis 12(11):1302–1315PubMed

75.

Steenholdt C, Brynskov J, Thomsen O et al (2014) Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 63(6):919–927PubMed

76.

Greuter T, Maillard MH, Juillerat P et al (2019) Therapeutic drug monitoring to guide clinical decision making in inflammatory bowel disease patients with loss of response to anti-TNF: a Delphi technique-based consensus. Digestion. https://doi.org/10.1159/000501930 CrossRefPubMed

77.

Hendy P, Hart A, Irving P (2016) Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide. Frontline Gastroenterol 7(2):122–128PubMed

78.

Jess T, Winther KV, Munkholm P et al (2002) Mortality and causes of death in Crohn’s disease: follow-up of a population-based cohort in Copenhagen county, Denmark. Gastroenterology 122(7):1808–1814PubMed

79.

Sandborn WJ, Fazio VW, Feagan BG et al (2003) American gastroenterological association clinical practice committee. AGA technical review on perianal Crohn’s disease. Gastroenterology 125(5):1508–1530PubMed

80.

Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A et al (2017) Management of complex perianal Crohn’s disease. Ann Gastroenterol 30(1):33–44PubMed

81.

Gecse KB, Bemelman W, Kamm MA et al (2014) A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut 63(9):1381–1392PubMed

82.

Adegbola SO, Pisani A, Sahnan K et al (2018) Medical and surgical management of perianal Crohn’s disease. Ann Gastroenterol 31(2):129–139PubMedPubMedCentral

83.

Wu XW, Ji HZ, Wang FY (2015) Meta-analysis of ciprofloxacin in treatment of Crohn’s disease. Biomed Rep 3(1):70–74PubMed

84.

Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340(18):1398–1405PubMed

85.

Lichtiger S, Binion DG, Wolf DC et al (2010) The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther 32(10):1228–1239PubMed

86.

Schreiber S, Lawrance IC, Thomsen O et al (2011) Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease—subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 33(2):185–193PubMed

87.

Jones JL, Kaplan GG, Peyrin-Biroulet L et al (2015) Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn’s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 13(13):2233–2240.e1‑2 (quiz e177-8)PubMed

88.

Lee MJ, Parker CE, Taylor SR et al (2018) Efficacy of medical therapies for fistulizing Crohn’s disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 16(12):1879–1892PubMed

89.

Biron C, Seksik P, Nachury M et al (2019) DOP74 Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multi-centre observational study. J Crohns Colitis. https://doi.org/10.1093/ecco-jcc/jjy222.108 CrossRef

90.

Ciccocioppo R, Klersy C, Leffler DA et al (2019) Systematic review with meta-analysis: safety and efficacy of local injections of mesenchymal stem cells in perianal fistulas. JGH Open 3(3):249–260PubMedPubMedCentral

91.

Pascua M, Su C, Lewis JD et al (2008) Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn’s disease. Aliment Pharmacol Ther 28(5):545–556PubMed

92.

Connelly TM, Messaris E (2014) Predictors of recurrence of Crohn’s disease after ileocolectomy: a review. World J Gastroenterol 20(39):14393–14406PubMedPubMedCentral

93.

Rutgeerts P, Geboes K, Vantrappen G et al (1990) Predictability of the postoperative course of Crohn’s disease. Gastroenterology 99(4):956–963PubMed

94.

Lamb CA, Kennedy NA, Raine T et al (2019) British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68(3):s1–s106PubMed

95.

Vaughn BP, Moss AC (2014) Prevention of post-operative recurrence of Crohn’s disease. World J Gastroenterol 20(5):1147–1154PubMedPubMedCentral

96.

Reese GE, Nanidis T, Borysiewicz C et al (2008) The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis 23(12):1213–1221PubMed

97.

Cosnes J, Carbonnel F, Beaugerie L et al (1996) Effects of cigarette smoking on the long-term course of Crohn’s disease. Gastroenterology 110(2):424–431PubMed

98.

Ryan WR, Allan RN, Yamamoto T et al (2004) Crohn’s disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg 187(2):219–225PubMed

99.

Rutgeerts P, Hiele M, Geboes K et al (1995) Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 108(6):1617–1621PubMed

100.

Nguyen GC, Loftus EV, Hirano I et al (2017) American gastroenterological association institute guideline on the management of Crohn’s disease after surgical resection. Gastroenterology 152(1):271–275PubMed

101.

Mowat C, Arnott I, Cahill A et al (2016) Mercaptopurine versus placebo to prevent recurrence of Crohn’s disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. Lancet Gastroenterol Hepatol 1(4):273–282PubMedPubMedCentral

102.

Regueiro M, Feagan BG, Zou B et al (2016) Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after Ileocolonic resection. Gastroenterology 150(7):1568–1578PubMed

103.

Iheozor-Ejiofor Z, Gordon M, Clegg A et al (2019) Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta-analysis. Cochrane Database Syst Rev 9:CD13210PubMed

Titel: Therapiealgorithmen für die Behandlung des Morbus Crohn im klinischen Alltag
verfasst von: PD Dr. med. Michael Christian Sulz
Joel Duetschler
Frank Seibold
Publikationsdatum: 14.05.2020
Verlag: Springer Vienna
Schlagwort: Morbus Crohn
Erschienen in: Schweizer Gastroenterologie / Ausgabe 2/2020
Print ISSN: 2662-7140
Elektronische ISSN: 2662-7159
DOI: https://doi.org/10.1007/s43472-020-00009-9

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

COVID-19 aus der Sicht der Gastroenterologie

Perorale endoskopische Myotomie vs. pneumatische Dilatation in der Behandlung der Achalasie

Editorial

Editoriale

Éditorial

Management der Hyperferritinämie